Neo-Bionica Announces the Appointment of Stéphane Chatonsky and Dr Colin White to its Board of Directors

Posted: 27 May 2024

Neo-Bionica welcomes two new non-executive directors with extensive international and business experience, to its board. Stéphane and Colin bring expertise that supports and strengthens Neo-Bionica’s domestic and international expansion plans.

Stéphane Chatonsky, MBA, GAICD is a highly experienced non-executive director and board chair, with deep expertise in finance and strategy within the technology and healthcare space. With over 25 years of international experience across Australia, Asia, and Europe, he has worked in investment banking with Lazard Freres and Macquarie Bank, strategy consulting at McKinsey, and in venture capital and private equity funds.

Stéphane currently serves as a non-executive director at Cerulea Clinical Trials; Genetic Signatures (ASX: GSS); Drop Bio Health; and Brainmates. He also serves as Chair at The CEO Institute, Honorary Fellow at Macquarie University, Adjunct Professor at the University of New South Wales, an expert-in-residence at Cicada Innovations and as an Expert Witness to the Federal Court of Australia.

Dr Colin White is a recognised business leader of technology-based businesses and has deep experience at driving high-performance organisations. Colin was Senior Vice President at Leica Biosystems, responsible for the company’s global advanced diagnostics business, overseeing manufacturing, supply chain, R&D, product management, and customer support functions, as well as over 800 associates.

Colin has served as the Managing Director at Invetech, a leader in providing contract design, development and manufacturing services for diagnostic products and cell therapy solutions. Additionally, Colin is a non-executive director at the Australian National Fabrication Facility.

Quotes attributable to Neo-Bionica CEO, Dr Ludovic Labat

“I am delighted to have Stéphane and Colin join the Neo-Bionica board. Their extensive expertise in innovation in MedTech, strategy and capital raising will be invaluable to Neo-Bionica as we enter our next phase of growth both domestically and internationally.”

Quotes attributable to Neo-Bionica Chair, Lusia Guthrie

“As Chair, I am very pleased to welcome Stéphane and Colin to our board. Their expertise and international outlook will augment our Board of Directors in overseeing the strategic, financial and managerial functions of the Company as we work with Ludovic’s team to achieve the Company’s ambitious growth objectives.”

Find out more.


News & opinion

Member Directory